Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2

Overview

Journal J Am Coll Cardiol

Specialty Cardiology & Vascular Diseases

Date 2017 Nov 18

PMID 29145955

Citations 124

Authors

Hui-Ming Chang

Tochukwu M Okwuosa

Tiziano Scarabelli

Rohit Moudgil

Edward T H Yeh

Affiliations

Soon will be listed here.

Abstract

In this second part of a 2-part review, we will review cancer or cancer therapy-associated systemic and pulmonary hypertension, QT prolongation, arrhythmias, pericardial disease, and radiation-induced cardiotoxicity. This review is based on a MEDLINE search of published data, published clinical guidelines, and best practices in major cancer centers. Newly developed targeted therapy can exert off-target effects causing hypertension, thromboembolism, QT prolongation, and atrial fibrillation. Radiation therapy often accelerates atherosclerosis. Furthermore, radiation can damage the heart valves, the conduction system, and pericardium, which may take years to manifest clinically. Management of pericardial disease in cancer patients also posed clinical challenges. This review highlights the unique opportunity of caring for cancer patients with heart problems caused by cancer or cancer therapy. It is an invitation to action for cardiologists to become familiar with this emerging subspecialty.

Citing Articles

Estimation of heart dose in left breast cancer radiotherapy: Assessment of vDIBH feasibility using the supervised machine learning algorithm.

Rajurkar S, Verma T, Gupta R J Appl Clin Med Phys. 2024; 26(2):e14595.

PMID: 39641663 PMC: 11799914. DOI: 10.1002/acm2.14595.

Abdominal aortic calcification among gastroenterological and transplant surgery.

Imaoka Y, Ohira M, Akabane M, Sasaki K, Ohdan H Ann Gastroenterol Surg. 2024; 8(6):987-998.

PMID: 39502733 PMC: 11533033. DOI: 10.1002/ags3.12816.

Cardiovascular disease in thymic cancer patients.

Khemka A, Clasen S, Loehrer P, Roberts A, Golzarri-Arroyo L, Badve S Front Cardiovasc Med. 2024; 11:1393631.

PMID: 39346095 PMC: 11427757. DOI: 10.3389/fcvm.2024.1393631.

Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease.

Jiang R, Lou L, Shi W, Chen Y, Fu Z, Liu S Int J Mol Sci. 2024; 25(18).

PMID: 39337662 PMC: 11432657. DOI: 10.3390/ijms251810177.

Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer.

Manhas A, Tripathi D, Thomas D, Sayed N Curr Cardiol Rep. 2024; 26(9):953-971.

PMID: 39042344 DOI: 10.1007/s11886-024-02099-2.

References

Gupta A, Lawrence A, Krishnan K, Kavinsky C, Trohman R . Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007; 153(6):891-9. DOI: 10.1016/j.ahj.2007.01.040. View

Streiff M, Holmstrom B, Ashrani A, Bockenstedt P, Chesney C, Eby C . Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. J Natl Compr Canc Netw. 2015; 13(9):1079-95. DOI: 10.6004/jnccn.2015.0133. View

Dequanter D, Lothaire P, Berghmans T, Sculier J . Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival. Ann Surg Oncol. 2008; 15(11):3268-71. DOI: 10.1245/s10434-008-0059-z. View

Darby S, McGale P, Taylor C, Peto R . Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005; 6(8):557-65. DOI: 10.1016/S1470-2045(05)70251-5. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Perez E, Rodeheffer R . Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004; 22(2):322-9. DOI: 10.1200/JCO.2004.01.120. View

Sane D, Anton L, Brosnihan K . Angiogenic growth factors and hypertension. Angiogenesis. 2004; 7(3):193-201. DOI: 10.1007/s10456-004-2699-3. View

Chen D, Zhang Y, Shi F, Zhu H, Li M, Luo J . Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients. Oncotarget. 2016; 7(32):52436-52441. PMC: 5239564. DOI: 10.18632/oncotarget.9420. View

Qi W, Min D, Shen Z, Sun Y, Lin F, Tang L . Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer. 2012; 132(12):2967-74. DOI: 10.1002/ijc.27979. View

10.

Ong D, Aertker R, Clark A, Kiefer T, Hughes G, Harrison J . Radiation-associated valvular heart disease. J Heart Valve Dis. 2014; 22(6):883-92. View

11.

Streitner F, Kuschyk J, Veltmann C, Ratay D, Schoene N, Streitner I . Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverter-defibrillator and an electrical storm. Cytokine. 2009; 47(3):166-72. DOI: 10.1016/j.cyto.2009.06.003. View

12.

Vorchheimer D . What is QT interval prolongation?. J Fam Pract. 2005; Suppl:S4-7. View

13.

Ederhy S, Cohen A, Dufaitre G, Izzedine H, Massard C, Meuleman C . QT interval prolongation among patients treated with angiogenesis inhibitors. Target Oncol. 2009; 4(2):89-97. DOI: 10.1007/s11523-009-0111-3. View

14.

Heidenreich P, Hancock S, Lee B, Mariscal C, Schnittger I . Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003; 42(4):743-9. DOI: 10.1016/s0735-1097(03)00759-9. View

15.

Carrier M, Cameron C, Delluc A, Castellucci L, Khorana A, Lee A . Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res. 2014; 134(6):1214-9. DOI: 10.1016/j.thromres.2014.09.039. View

16.

Choueiri T, Schutz F, Je Y, Rosenberg J, Bellmunt J . Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010; 28(13):2280-5. DOI: 10.1200/JCO.2009.27.2757. View

17.

Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A . Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012; 125(17):2128-37. DOI: 10.1161/CIRCULATIONAHA.111.079921. View

18.

Kamba T, McDonald D . Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007; 96(12):1788-95. PMC: 2359962. DOI: 10.1038/sj.bjc.6603813. View

19.

Ghatalia P, Je Y, Kaymakcalan M, Sonpavde G, Choueiri T . QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 2014; 112(2):296-305. PMC: 4453446. DOI: 10.1038/bjc.2014.564. View

20.

Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H . Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2):315-352. DOI: 10.1016/j.chest.2015.11.026. View